Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Teva
Baxter
Mallinckrodt
Dow
Argus Health
Colorcon
Express Scripts
Healthtrust
US Department of Justice

Generated: August 23, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 7,473,686 protect, and when does it expire?


Patent ► Subscribe protects PROMACTA and is included in two NDAs. There have been two Paragraph IV challenges on Promacta.

Protection for PROMACTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-three patent family members in twenty-eight countries.

Summary for Patent: ► Subscribe

Title:Thrombopoietin mimetics
Abstract:Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Inventor(s): Duffy; Kevin J. (Collegeville, PA), Erickson-Miller; Connie (King Of Prussia, PA), Jenkins; Julian (Collegeville, PA), Luengo; Juan I. (Collegeville, PA), Visonneau; Sophie (Collegeville, PA)
Assignee: SmithKline Beecham Corp. (Philadelphia, PA)
Application Number:11/650,651
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Delivery; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
FOR SUSPENSION;ORAL207027-001Aug 24, 2015RXYesYes► Subscribe► SubscribeY
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
TABLET;ORAL022291-004Oct 20, 2011RXYesNo► Subscribe► SubscribeY
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
TABLET;ORAL022291-001Nov 20, 2008RXYesNo► Subscribe► SubscribeY
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
TABLET;ORAL022291-002Nov 20, 2008RXYesNo► Subscribe► SubscribeY
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
TABLET;ORAL022291-003Sep 8, 2009RXYesYes► Subscribe► SubscribeY
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
TABLET;ORAL022291-005Nov 16, 2012RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,790,704Thrombopoietin mimetics► Subscribe
7,160,870Thrombopoietin mimetics► Subscribe
7,452,874Thrombopoietin mimetics► Subscribe
7,335,649Thrombopoietin mimetics► Subscribe
7,674,887Thrombopoietin mimetics► Subscribe
7,332,481Thrombopoietin mimetics► Subscribe
7,439,342Thrombopoietin mimetics► Subscribe
7,648,971Thrombopoietin mimetics► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina030696► Subscribe
Argentina066036► Subscribe
Austria374772► Subscribe
Austria445606► Subscribe
Australia2001274938► Subscribe
Australia7493801► Subscribe
Brazil0111116► Subscribe
Canada2411468► Subscribe
China100423721► Subscribe
China101342169► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Covington
Daiichi Sankyo
Harvard Business School
Chubb
Chinese Patent Office
McKesson
Medtronic
Johnson and Johnson
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot